Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidanceJuly 29, 2025 Novo Nordisk shares dropped 20% after cutting full-year guidance and naming a new CEO, citing U.S. market weakness for Wegovy and Ozempic.
